China NMPA Product Recall - Disposable biopsy needle

Bard Medical Technology (Shanghai) Co., Ltd. implemented a voluntary Class II recall for specific batches of its disposable biopsy needles, effective November 13, 2017. This significant action, overseen by the National Medical Products Administration (NMPA), was initiated due to critical performance deficiencies identified in the medical devices. The main issues reported included difficulties in the initiation and activation of the biopsy needles, which could prevent clinicians from performing the intended procedure effectively. Additionally, there were instances where the devices failed to obtain adequate tissue samples, potentially leading to diagnostic delays or inaccuracies. A serious safety concern also emerged with reports of devices self-activating after initial deployment, presenting a significant hazard during medical interventions. The recall encompasses particular models, specifications, and batch numbers of these devices, specifically those marketed under the trade name Max-Core, with comprehensive details documented in the official 'Medical Device Recall Event Report' and its supplementary forms. This proactive recall demonstrates the company's commitment to upholding product quality and ensuring patient safety by addressing potential risks associated with these vital medical instruments.